0001558370-23-015012.txt : 20230816 0001558370-23-015012.hdr.sgml : 20230816 20230816074512 ACCESSION NUMBER: 0001558370-23-015012 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230816 ITEM INFORMATION: Other Events FILED AS OF DATE: 20230816 DATE AS OF CHANGE: 20230816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elevation Oncology, Inc. CENTRAL INDEX KEY: 0001783032 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 841771427 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40523 FILM NUMBER: 231176498 BUSINESS ADDRESS: STREET 1: 101 FEDERAL STREET STREET 2: SUITE 1900 CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 7163711125 MAIL ADDRESS: STREET 1: 101 FEDERAL STREET STREET 2: SUITE 1900 CITY: BOSTON STATE: MA ZIP: 02110 FORMER COMPANY: FORMER CONFORMED NAME: 14ner Oncology, Inc. DATE OF NAME CHANGE: 20190719 8-K 1 elev-20230816x8k.htm 8-K
0001783032false00017830322023-08-162023-08-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 16, 2023

Elevation Oncology, Inc.

(Exact name of Registrant as Specified in its Charter)

Delaware

001-40523

84-1771427

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

101 Federal Street, Suite 1900

Boston, Massachusetts

02110

(Address of Principal Executive Offices)

(Zip Code)

(716) 371-1125

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001 per share

ELEV

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01

Other Events.

On August 16, 2023, Elevation Oncology, Inc. (the “Company”) announced that the first patient has been dosed in the Phase 1 clinical trial evaluating EO-3021 in patients with advanced unresectable or metastatic solid tumors likely to express Claudin 18.2 including gastric, gastroesophageal junction, pancreatic or esophageal cancers. The Company expects to report preliminary safety and anti-tumor data from its Phase 1 study during the first half of 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Elevation Oncology, Inc.

Date: August 16, 2023

By:

/s/ Tammy Furlong

Tammy Furlong

Chief Financial Officer

EX-101.SCH 2 elev-20230816.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 elev-20230816_def.xml EX-101.DEF EX-101.LAB 4 elev-20230816_lab.xml EX-101.LAB EX-101.PRE 5 elev-20230816_pre.xml EX-101.PRE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Aug. 16, 2023
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Aug. 16, 2023
Entity Registrant Name Elevation Oncology, Inc.
Entity File Number 001-40523
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 84-1771427
Entity Address, Address Line One 101 Federal Street
Entity Address, Address Line Two Suite 1900
Entity Address, City or Town Boston
Entity Address State Or Province MA
Entity Address, Postal Zip Code 02110
City Area Code 716
Local Phone Number 371-1125
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol ELEV
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001783032
Amendment Flag false
XML 7 elev-20230816x8k_htm.xml IDEA: XBRL DOCUMENT 0001783032 2023-08-16 2023-08-16 0001783032 false 8-K 2023-08-16 Elevation Oncology, Inc. DE 001-40523 84-1771427 101 Federal Street Suite 1900 Boston MA 02110 716 371-1125 false false false false Common stock, par value $0.0001 per share ELEV NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 24 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://elevationoncology.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports elev-20230816x8k.htm elev-20230816.xsd elev-20230816_def.xml elev-20230816_lab.xml elev-20230816_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "elev-20230816x8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "elev-20230816_def.xml" ] }, "inline": { "local": [ "elev-20230816x8k.htm" ] }, "labelLink": { "local": [ "elev-20230816_lab.xml" ] }, "presentationLink": { "local": [ "elev-20230816_pre.xml" ] }, "schema": { "local": [ "elev-20230816.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "elev", "nsuri": "http://elevationoncology.com/20230816", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "elev-20230816x8k.htm", "contextRef": "Duration_8_16_2023_To_8_16_2023_Cl38eC5o8EWdH8EPxDO8uQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "elev-20230816x8k.htm", "contextRef": "Duration_8_16_2023_To_8_16_2023_Cl38eC5o8EWdH8EPxDO8uQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001558370-23-015012-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-015012-xbrl.zip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end